Immunovant Change In Cash from 2010 to 2024

IMVT Stock  USD 28.79  0.59  2.09%   
Immunovant Change In Cash yearly trend continues to be comparatively stable with very little volatility. Change In Cash will likely drop to about 325 K in 2024. From the period from 2010 to 2024, Immunovant Change In Cash quarterly data regression had mean square error of 10716.8 T and mean deviation of  75,069,644. View All Fundamentals
 
Change In Cash  
First Reported
2018-06-30
Previous Quarter
-75.4 M
Current Value
-87.1 M
Quarterly Volatility
94.8 M
 
Covid
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 34.8 M or Other Operating Expenses of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.8 K. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
  
Check out the analysis of Immunovant Correlation against competitors.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Latest Immunovant's Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Immunovant over the last few years. It is Immunovant's Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
       Timeline  

Immunovant Change In Cash Regression Statistics

Arithmetic Mean45,660,667
Coefficient Of Variation232.03
Mean Deviation75,069,644
Median6,985,000
Standard Deviation105,946,467
Sample Variance11224.7T
Range416.9M
R-Value0.34
Mean Square Error10716.8T
R-Squared0.11
Significance0.22
Slope7,979,193
Total Sum of Squares157145.2T

Immunovant Change In Cash History

2023258.8 M
2022-117.3 M
202193.7 M
2020299.6 M
201993.6 M
2018325 K

About Immunovant Financial Statements

Immunovant shareholders use historical fundamental indicators, such as Change In Cash, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Cash258.8 M325 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.